Actively Recruiting
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Led by M.D. Anderson Cancer Center · Updated on 2026-04-15
140
Participants Needed
1
Research Sites
731 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial studies methylprednisolone, horse anti-thymocyte globulin, cyclosporine, filgrastim, and/or pegfilgrastim or pegfilgrastim biosimilar in treating patients with aplastic anemia or low or intermediate-risk myelodysplastic syndrome. Horse anti-thymocyte globulin is made from horse blood and targets immune cells known as T-lymphocytes. Since T-lymphocytes are believed to be involved in causing low blood counts in aplastic anemia and in some cases of myelodysplastic syndromes, killing these cells may help treat the disease. Methylprednisolone and cyclosporine work to suppress immune cells called lymphocytes. This may help to improve low blood counts in aplastic anemia and myelodysplastic syndromes. Filgrastim and pegfilgrastim are designed to cause white blood cells to grow. This may help to fight infections and help improve the white blood cell count. Giving methylprednisolone and horse anti-thymocyte globulin together with cyclosporine, filgrastim, and/or pegfilgrastim may be an effective treatment for patients with aplastic anemia or myelodysplastic syndrome.
CONDITIONS
Official Title
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with myelodysplastic syndrome (low, intermediate-1 by IPSS, or hypocellular), previously treated or untreated
- Patients diagnosed with aplastic anemia, previously treated or untreated, who are not candidates for allogeneic stem cell transplant
- Age 18 years or older
- Off cytotoxic, immunosuppressive (except steroids), or targeted therapy for at least 2 weeks and recovered to grade 1 or less from toxic effects
- Adequate liver function (bilirubin less than 2 mg/dL, AST less than 3 times upper limit of normal)
- Adequate kidney function (creatinine less than 2.5 times upper limit of normal)
- ECOG performance status of 2 or less
- Women of child-bearing potential and men must agree to use adequate contraception during the study
- Negative urine pregnancy test within 1 week prior to enrollment for women of childbearing potential
- Ability to understand study requirements and provide signed informed consent
- Indication for therapy such as transfusion dependence or morbidity related to cytopenias like bleeding, severe fatigue, or frequent infections
You will not qualify if you...
- Pregnant women
- Nursing mothers (breastfeeding should be discontinued if treated on study)
- Known HIV infection
- Uncontrolled illness including active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social conditions limiting study compliance
- Documented hypersensitivity to any study medication components
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
T
Tapan Kadia, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here